What it Means to Demonstrate Target Engagement in Therapies that Target the Immune System: Role of Combination of Biomarkers.
Time: 2:00 pm
day: Day Two
- Assessing target engagement of inflammatory treatments via multiple platforms and assays; why is it necessary?
- “Anti-inflammatory” is not enough: Demonstrate downstream consequences of targeting inflammation
- Integrating novel, non-invasive biomarkers, in early-stage trials – potential and limitations.